ストックスクリーナーアプリを入手
7.77
1.15%
-0.09
アフターアワーズ：
7.77
前日終値:
$7.86
開ける：
$7.98
24時間の取引高:
1.15M
Relative Volume:
0.62
時価総額：
$1.01B
収益：
$727.33M
当期純損益:
$-108.03M
株価収益率:
-9.2062
EPS:
-0.844
ネットキャッシュフロー:
$-21.78M
1週間 パフォーマンス:
-3.00%
1か月 パフォーマンス:
-20.88%
6か月 パフォーマンス:
-1.21%
1年 パフォーマンス:
-21.99%
1日の値動き範囲:
$7.68
$8.10
1週間の範囲:
$7.68
$8.34
52週間の値動き範囲:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Compare NEO vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.77 | 1.02B | 727.33M | -108.03M | -21.78M | -0.844 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 開始されました | Guggenheim | Neutral |
| 2025-04-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 開始されました | Jefferies | Buy |
| 2024-05-01 | 再開されました | Craig Hallum | Buy |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-08-21 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-02-24 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-02-01 | アップグレード | Needham | Hold → Buy |
| 2022-08-26 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-08-22 | ダウングレード | Needham | Buy → Hold |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-03-29 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-29 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 再開されました | Stephens | Overweight |
| 2021-12-16 | 開始されました | Cowen | Outperform |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-02-25 | 再開されました | Needham | Buy |
| 2021-02-25 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-12-11 | 再開されました | BTIG Research | Buy |
| 2020-10-28 | 繰り返されました | Needham | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-08-28 | 開始されました | Guggenheim | Buy |
| 2020-07-29 | 繰り返されました | Needham | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Buy |
| 2020-04-21 | 再開されました | Stephens | Overweight |
| 2020-03-02 | 再開されました | Craig Hallum | Buy |
| 2020-02-28 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | ダウングレード | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 繰り返されました | Needham | Buy |
| 2019-05-01 | 繰り返されました | Needham | Buy |
| 2019-03-29 | 繰り返されました | Needham | Buy |
| 2019-01-03 | 開始されました | Needham | Buy |
| 2018-10-24 | アップグレード | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 開始されました | Leerink Partners | Outperform |
| 2018-05-02 | ダウングレード | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | ダウングレード | BTIG Research | Buy → Neutral |
| 2017-08-24 | 開始されました | Gabelli & Co | Buy |
| 2016-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Neogenomics Inc (NEO) 最新ニュース
Dip Buying: Whats the analyst consensus on NeoGenomics Inc2026 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
NeoGenomics invites engagement on innovation in oncology at USCAP event - Traders Union
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Aug PreEarnings: Is NeoGenomics Inc stock a falling knife or bargain buyTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Retail: Is NeoGenomics Inc gaining market share2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Aug Chart Watch: Can NeoGenomics Inc deliver alpha2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
NEO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeoGenomics (NEO) launches RaDaR ST to capture share in $20B MRD market - MSN
Discipline and Rules-Based Execution in NEO Response - Stock Traders Daily
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO) - simplywall.st
NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market - Insider Monkey
11 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
NeoGenomics offers preview of booth presence at USCAP2026 - Traders Union
NeoGenomics Beats Investor Suit Over Growth Driver Claims - Law360
Will Medicare Coverage for PanTracer LBx Liquid Biopsy Shift NeoGenomics' (NEO) Diagnostic Narrative? - Yahoo Finance
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges - Markets Mojo
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - simplywall.st
NeoGenomics’ PanTracer LBx test receives Medicare coverage By Investing.com - Investing.com Australia
NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026 - Meyka
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit - Bloomberg Law News
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling - BioSpace
William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test By Investing.com - Investing.com Australia
Neogenomics stock gets MolDX reimbursement for cancer test By Investing.com - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test - Investing.com
NeoGenomics test gains Medicare coverage for cancer care - Gulfshore Business
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biop - pharmiweb.com
Neogenomics stock gets MolDX reimbursement for cancer test - Investing.com
Neogenomics IncPantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program - TradingView
NeoGenomics’ PanTracer LBx test receives Medicare coverage - Investing.com
NeoGenomics, Inc. $NEO Stock Position Increased by First Light Asset Management LLC - MarketBeat
Silverback Asset Management LLC Invests $1.55 Million in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping - Traders Union
Liquid Biopsy Market to Reach US$28.20 Billion by 2033 at 12.8% - openPR.com
NeoGenomics (NEO) Price Target Increased by 21.45% to 12.44 - MSN
NeoGenomics announces launch of new cancer assay PanTracer Pro - MSN
Trend Review: Can NeoGenomics Inc keep up with sector leadersQuarterly Trade Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Stock Price Down 7.9%Should You Sell? - MarketBeat
Greenhouse Funds LLLP Acquires 789,510 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics at Leerink Conference: Strategic Growth Focus By Investing.com - Investing.com India
Neogenomics Inc (NEO) 財務データ
収益
当期純利益
現金流量
EPS
0.19%
0.04%
大文字化:
|
ボリューム (24 時間):